These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7515925)

  • 1. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
    Praz F; Lesavre P
    J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
    Seya T; Hara T; Matsumoto M; Akedo H
    J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
    Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
    J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
    Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
    Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
    Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
    Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
    Nemerow GR; McNaughton ME; Cooper NR
    J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
    Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
    Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement-activating ability of leucocytes from patients with complement factor I deficiency.
    Marquart HV; Rasmussen JM; Leslie RG
    Immunology; 1997 Jul; 91(3):486-92. PubMed ID: 9301541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
    Olesen EH; Johnson AA; Damgaard G; Leslie RG
    Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
    Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
    Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
    Leslie RG; Prodinger WM; Nielsen CH
    Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures.
    Döpper S; Wilflingseder D; Prodinger WM; Stiegler G; Speth C; Dierich MP; Stoiber H
    Eur J Immunol; 2003 Aug; 33(8):2098-107. PubMed ID: 12884283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
    Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
    J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.